以减少肿瘤复发并实现患者满意度为目标，免疫疗法的引发及其综合协同应用是肿瘤治疗的一个光明的新方向，但也是一项新兴的挑战性任务。特别是，通过光诱导光动力和光热疗法（PDT和PTT）进行肿瘤相关巨噬细胞（TAM）调节被认为是一种强大的方法，其重点是全身免疫系统而不是肿瘤本身。在此，本研究报道了一种受体-供体-受体（A-D-A）聚集诱导发光体（AIEgen），命名为TPA-2CN，它被用作光敏剂（PS）和光热剂（PTA）。由于其 A-D-A 结构和 AIE 特性，TPA-2CN 表现出高摩尔吸收系数，可作为调节主要利用激发能的辐射和非辐射跃迁的完美模板。 I型活性氧的产生促进了其在缺氧肿瘤部位的应用，并且高热的结合有力地诱导巨噬细胞向免疫反应M1表型极化。在体外和体内，免疫微环境的成功逆转和重新编程得到了令人印象深刻的证明。该方法将免疫疗法、PDT和PTT最佳集中为一体，表现出优异的协同治疗效果和良好的生物安全性。

Aiming to decrease the recurrence of tumors and achieve patient satisfaction, the elicitation of immunotherapy and its integrated synergistic employment is a bright new direction in oncotherapy, yet an emergently challenging task. In particular, tumor-associated macrophage (TAM) regulation though light-induced photodynamic and photothermal therapy (PDT and PTT) is regarded as a powerful approach, which focuses on the systemic immune system instead of the tumor itself. Herein, this study reports an acceptor-donor-acceptor (A-D-A) aggregation-induced emission luminogen (AIEgen), named TPA-2CN, which was applied as a photosensitizer (PS) and photothermal agent (PTA). Attributed to its A-D-A structure and AIE properties, TPA-2CN exhibits a high molar absorption coefficient and acts as a perfect template in regulating radiative and nonradiative transitions, which mainly utilize excited energy. The generation of type I reactive oxygen promoted its application in hypoxic tumor sites and the combination of hyperpyrexia forcefully induces macrophages to polarize towards the immune response M1 phenotype. In in vitro and in vivo, the successful reversion and reprogramming of the immune microenvironment was impressively proved. This method optimally concentrated immune therapy, PDT and PTT as one and exhibited excellent synergistic therapeutic effects with good biosafety.